首页> 外国专利> CELL-TARGETING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES.

CELL-TARGETING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES.

机译:包含志贺毒素A亚单位效应子和CD8 + T细胞表位的细胞靶向分子。

摘要

The present invention provides cell-targeting molecules which can deliver a CD8+ T-cell epitope cargo to the MHC class I presentation pathway of the cell. The cell-targeting molecules of the invention can be used to deliver virtually any CD8+ T-cell epitope from an extracellular space to the MHC class I pathway of a target cell, which may be a malignant cell and/or non-immune cell. The target cell can then display on a cell-surface the delivered CD8+ T-cell epitope complexed with MHC I molecule. The cell-targeting molecules of the invention have uses which include the targeted labeling and/or killing of specific cell-types within a mixture of cell-types, including within a chordate, as well as the stimulation of beneficial immune responses. The cell-targeting molecules of the invention have uses, e.g., in the treatment of a variety of diseases, disorders, and conditions, including cancers, tumors, growth abnormalities, immune disorders, and microbial infections.
机译:本发明提供了细胞靶向分子,其可以将CD8 + T细胞表位货物递送至细胞的MHC I类呈递途径。本发明的靶向细胞的分子可用于将几乎任何CD8 + T细胞表位从细胞外空间递送至靶细胞的MHC I类途径,靶细胞可以是恶性细胞和/或非免疫细胞。然后靶细胞可以在细胞表面展示与MHC I分子复合的递送的CD8 + T细胞表位。本发明的靶向细胞的分子具有的用途包括靶向标记和/或杀死细胞类型混合物中的特定细胞类型,包括在a酸盐中,以及刺激有益的免疫反应。本发明的靶向细胞的分子具有例如用于治疗多种疾病,病症和病状的用途,包括癌症,肿瘤,生长异常,免疫病症和微生物感染。

著录项

  • 公开/公告号MX2018001208A

    专利类型

  • 公开/公告日2018-03-26

    原文格式PDF

  • 申请/专利权人 MOLECULAR TEMPLATES INC.;

    申请/专利号MX20180001208

  • 发明设计人 ERIC POMA;ERIN WILLERT;JASON KIM;

    申请日2016-07-25

  • 分类号C07K16/28;C07K16/32;

  • 国家 MX

  • 入库时间 2022-08-21 12:51:08

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号